Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 3, 2007, Pages 285-293

  Zhu, Andrew X ^a,c   Clark, Jeffrey W ^a,c   Ryan, David P ^a,c   Meyerhardt, Jeffrey A ^b,c   Enzinger, Peter C ^b,c   Earle, Craig C ^b,c   Fuchs, Charles S ^b,c,d   Regan, Eileen ^a   Anbe, Hiroshi ^e   Houghton, Michele ^e   Zhang, Joshua ^e   Urrea, Peter ^e   Kulke, Matthew H ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Taiho Pharma USA Inc   (United States)

Author keywords

5 Fluorouracil (5 FU); Antitumor activity; Gastrointestinal malignancies; Pharmacokinetics; Phase I; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; TEGAFUR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; FEVER; GALLBLADDER CARCINOMA; HAND FOOT SYNDROME; HUMAN; HYPONATREMIA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; RASH; SIDE EFFECT; SODIUM BLOOD LEVEL; STOMACH CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OXONIC ACID; TEGAFUR; UPPER GASTROINTESTINAL TRACT;

EID: 33845882231     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0265-y     Document Type: Article

References (40)

1. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P (2005) Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23:6957-6965
2. Ajani JA, Lee F-C, Singh DA, Haller DG, Lenz H-J, Benson III AB, Yanagihara R, Phan AT, Yao JC, Strumberg D (2006) Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24:663-667
3. Cancer Therapy Evaluation Program (2003) Common terminology criteria for adverse advents. DCTD. NCI. NIH. DHHS, V.3.0. http://www.ctep.cancer.gov. Cited 10 June 2003
4. Chollet P, Schöffski P, Weigang-Köhler K, Schellens JHM, Cure H, Pavlidis N, Grunwald V, De Boer R, Wanders J, Fumoleau (2003) Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 39:1264-1270
5. Cocconi G, Carlini P, Gamboni A, Gasperoni S, Rodino C, Zironi S, Bisagni G, Porrozzi S, Cognetti F, Di Costanzo F, Canaletti R, Ruggeri EM, Camisa R, Pucci F (2003) Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol 14:1258-1263
6. Cohen SJ, Leichman CG, Yeslow G, Beard M, Proefrock A, Roedig B, Damle B, Letrent SP, DeCillis AP, Meropol NJ (2002) Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin Cancer Res 8:2116-2122
7. Fujii M, Endo S, Tomita K, Nishijima W, Tsukuda M, Hasegawa Y, Ishitoya J, Yamane H, Fujii H, Honma A, Tomita T (2005) A phase I/II study of S-1 plus cisplatin (CDDP) in patients with head and neck cancer (HNC) (Meeting Abstracts). J Clin Oncol 23:5552
8. Furuse K, Kawahara M, Hasegawa K, Kudoh S, Takada M, Sugiura T, Ichinose Y, Fukuoka M, Ohashi Y, Niitani H, for the S-1 Cooperative Study Group (Lung Cancer Working Group) (2001) Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer. Int J Clin Oncol 6:236-241
9. Furuse J, Okusaka T, Funakoski A, Boku N, Yamao K, Ohkawa S, Saito H (2005) A phase II study of S-1 in patients with metastatic pancreatic cancer (Meeting Abstracts). J Clin Oncol 23(16S):4104
10. Hino M, Saeki T, Sato Y, Sano M (2004) Late phase II study of S-1 in patients with taxane resistant breast cancer (Meeting Abstracts). J Clin Oncol 22:745
11. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T (1999) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5:2000-2005
12. Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R (2003) Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 9:134-142
13. Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, Niitani H (2004) S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 10:7860-7864
14. Ikeda K, Yoshisue K, Matsushima E, Nagayama S, Kobayashi K, Tyson CA, Chiba K, Kawaguchi Y (2000) Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 6:4409-4415
15. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B (1998) Early phase II study of S-1 in patients with advanced head and neck cancer. Jpn J Cancer Chemother 25:1151-1158
16. Kajita J, Fuse E, Kuwabara T, Kobayashi H (2003) The contribution of cytochrome P450 to the metabolism of tegafur in human liver. Drug Metab Pharmacokinet 18:303-309
17. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsul K, Kudoh S, Hasegawa K, Niitani H, S-1 Cooperative Study Group (Lung Cancer Working Group) (2001) Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Brit J Cancer 85:939-943
18. Koizumi W, Kurihara M, Nakano S, Hasegawa K, for the S-1 Cooperative Gastric Cancer Study Group (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58:191-197
19. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y, Gotoh M (2003) Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Brit J Cancer 89:2207-2212
20. Matsushima E, Yoshida K, Kitamura R, Yoshida K (1997) Determination of S-1 (combined drug tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography negative ion chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 691:95-104
21. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T, for the S-1 Cooperative Colorectal Carcinoma Study Group (2000) Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. Brit J Cancer 83:141-145
22. Peters GJ, Noordhuis P, van Groeningen CJ, Giaccone G, Holwerda U, Voorn D, Schrijvera A, Schornagel JH, Beijnen JH, Fumoleau P, Schellens JHM (2004) The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clin Cancer Res 10:4072-4076
23. Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, Ross PJ, Oates J, Norman AR (2005) Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Brit J Cancer 92:1650-1654
24. Rani M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R (2005) Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicrentre phase III trial. Lancet Oncol 6:369-376
25. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715-1720
26. Sano M, Saeki T, Takashima S, Horikoshi N, Miura S, Morimoto K, Noguchi S, Taguchi T (2000) Late phase II study of S-1 in patients with advanced and/or recurrent breast cancer (Meeting Abstracts). J Clin Oncol 18:404
27. Shimada T, Yamazaki H, Guengerich FP (1996) Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 26:395-403
28. Shirao K, Ohtsu A, Takada H, Mitachi Y, Hakawa K, Horikoshi N, Okamura T, Hirata K, Saitoh S, Isomoto H, Satoh A (2004) Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 100:2355-2361
29. Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53:4004-4009
30. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs 7:548-557
31. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, Taguchi T, The S-1 Gastrointestinal Cancer Study Group (1999) An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 57:202-210
32. Taguchi T, Morimoto K, Horikoshi N, Takashima S, Toge T, Kimura M, Sano M, Aoyama H, Ota J, Noguchi S (1998) An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group). Jpn J Cancer Chemother 25:1035-1043
33. Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, Unemi N, Shirasaka T (1997) Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39:205-211
34. Tatsumi K, Fukushima M, Shirasaka T, Fujii S (1987) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res (Gann) 78:748-755
35. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
36. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C (2004) Phase II study of S-1 in patents with advanced biliary tract cancer. Brit J Cancer 91:1769-1774
37. Van den Brande J, Schöffski P, Schellens JHM, Roth AD, Duffaud F, Weigang-Kohler K, Reinke F, Wanders J, de Boer RF, Vermorken JB, Fumoleau P (2003) EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Brit J Cancer 88:648-653
38. Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, Turner SL, Swart MS, Pinedo HM, Hanauske AR, Giaccone G (2000) Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 18:2772-2779
39. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Dos Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll H-J, Bleiberg H, Nordlinger B, Couvreur M-L, Baron B, Wils JA (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European organization for research and treatment of cancer gastrointestinal tract cancer cooperative group. J Clin Oncol 18:2648-2657
40. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Jaffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-267